111 results
8-K
ORGS
Orgenesis Inc
29 Dec 23
Departure of Directors or Certain Officers
4:05pm
Development, Business Development, Marketing and Strategy while working for Baxter Healthcare and Giles & Associates.
From 1996 to 2000, Mr. Miller gained
424B5
ORGS
Orgenesis Inc
9 Nov 23
Prospectus supplement for primary offering
7:41am
regarding our strategy, future operations, future financial position, future revenues, and projected costs, prospects, plans and objectives of management … partners and manufacturing availability;
our ability to implement our POC strategy in order to further develop and advance autologous therapies to reach
8-K
EX-99.1
oq2k0d9195xzhv7llidx
8 Nov 23
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
9:24am
8-K
EX-99.1
lns cy7uglr1q45od
31 Oct 23
Orgenesis Announces Withdrawal of Proposed Public Offering
6:02am
424B5
tmqftt3xdhjg30nhl5
30 Oct 23
Prospectus supplement for primary offering
5:07pm
424B3
b1dsvlpv3lx766dk
4 Apr 23
Prospectus supplement
3:18pm
8-K
EX-99.1
3bo8c1bp1
5 Apr 22
Orgenesis Inc. Announces $14.8 Million Private Placement
5:10pm
8-K
EX-99.1
bn2sbj
30 Mar 22
Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update
7:29am